B

BioMarin Pharmaceutical

D

BMRN

USD

0.57

(0.8081%)

Market Closed

91,406.00

حجم التداول

2.87

الربح لكل سهم

-

العائد الربحي

53.871

P/E

13,538,122,472.42

حجم السوق

اليوم

0.8081%

1 اسبوع

-16.114%

1 شهر

-20.556%

6 اشهر

-15.194%

12 اشهر

-19.759%

بداية السنة

-26.250%

كل الوقت

0%

أصول ذات صلة

أفضل المتداولين

Title:
BioMarin Pharmaceutical

Sector:

Healthcare

Industry:

Biotechnology

BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.

هل تحتاج مساعدة او لديك استفسار؟

تواصل معنا